Cancer Genetics to Present New Data From Renal Cell Carcinoma Study at AACR

Cancer Genetics to Present New Data From Renal Cell Carcinoma Study at AACR

Genomic Alterations Identified in Study Could Potentially Serve as Biomarkers
for Metastasis in RCC

RUTHERFORD, N.J., April 3, 2014 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc.
(Nasdaq:CGIX), an emerging leader in DNA-based diagnostics, announced today
that a poster highlighting preliminary results of a study in clear cell Renal
Cell Carcinoma (ccRCC) will be presented at the 105^th Annual Meeting of the
American Association of Cancer Research ("AACR"), which will be held in San
Diego, California April 5-9, 2014.

Date:          Sunday, April 6, 2014
Time:          1pm – 5pm Pacific
Session Title: Biomarkers of Tumor Metastasis
Title:         Identification of Genomic Alterations Associated with
               Metastasis in Clear Cell Renal Cell Carcinoma

The study, conducted by Cancer Genetics in collaboration with researchers from
Memorial Sloan-Kettering Cancer Center, was designed to identify genomic copy
number alterations by a high-resolution approach (whole genome array-CGH) that
could serve as biomarkers for tumor metastasis in clear cell renal
carcinoma.The poster highlights results from 16 significant aberrations that
were identified to occur at higher frequencies in metastatic compared to
primary samples across unmatched and matched analyses.The authors suggested
that upon further validations, including prospective studies, such aberrations
could serve as biomarkers of metastatic disease and, therefore, could be
helpful in risk-stratification and clinical management of low stage ccRCC
patients.Also in this study, metastatic site-specific aberrations were
identified that could be useful in defining subclinical disease and to help
understand the biology of those metastasis.

Clear Cell Renal Cell Carcinoma accounts for approximately 70% of all renal
cortical neoplasms.Metastatic ccRCC is well known for its aggressive nature
and poor prognosis, with approximately 20-40% of patients relapsing within 5
years of nephrectomy.Also, metastatic ccRCC is largely refractory to
conventional treatments with a five-year survival rate of approximately 8-9%,
whereas targeted therapies are proven to increase overall survival
rates.Treatment options vary depending on the site of metastasis.

This is the first year Cancer Genetics will have a presence at AACR. Company
representatives will be located at Booth #445.

Cancer Geneticsis alsotheprimarysponsor of the Society of American Asian
Scientists in Cancer Research annual dinner meeting, to be held on April
6that The San Diego Woman's Clubat 6pm Pacific Time.Approximately 500
scientists, clinicians and researcherswill gather to present awards to the
five top scientists, researchers and contributors to cancer research.

About Cancer Genetics:

Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics,
servicing some of the most prestigious medical institutions in the world. Our
tests target cancers that are difficult to diagnose and predict treatment
outcomes. These cancers include hematological, urogenital and HPV-associated
cancers. We also offer a comprehensive range of non-proprietary
oncology-focused tests and laboratory services that provide critical genomic
information to healthcare professionals, as well as biopharma and biotech
companies. Our state-of-the-art reference lab is focused entirely on
maintaining clinical excellence and is both CLIA certified and CAP accredited
and has licensure from several states including New York State. We have
established strong research collaborations with major cancer centers such as
Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National
Cancer Institute. For further information, please see www.cancergenetics.com.

Forward Looking Statements: This press release contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. All statements pertaining to future financial and/or operating
results, future growth in research, technology, clinical development and
potential opportunities for Cancer Genetics, Inc. products and services, along
with other statements about the future expectations, beliefs, goals, plans, or
prospects expressed by management constitute forward-looking statements. Any
statements that are not historical fact (including, but not limited to,
statements that contain words such as "will," "believes," "plans,"
"anticipates," "expects," "estimates") should also be considered to be
forward-looking statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, risks inherent in the
development and/or commercialization of potential products, uncertainty in the
results of clinical trials or regulatory approvals, need and ability to obtain
future capital, maintenance of intellectual property rights and other risks
discussed in the Company's Form 10-K for the year ended December 31, 2013 and
other filings with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date hereof. Cancer Genetics
disclaims any obligation to update these forward-looking statements.

CONTACT: Investor Relations
         Michael Rice
         Life Science Advisors LLC
         646-597-6979
        
         Media Relations
         RedChip Companies, Inc.
         Paul Kuntz, 800-733-2447, ext. 105
         paul@redchip.com
 
Press spacebar to pause and continue. Press esc to stop.